CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks
Status:
Active, not recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a multicenter, double-blind, randomized, placebo-controlled, parallel-arm study to
investigate the efficacy and safety of subcutaneous administration of CSL312 (garadacimab) in
the prophylactic treatment of hereditary angioedema